Ingevity Corporation (NYSE:NGVT), a specialty chemicals and materials company, has reported a significant change in its executive team. The company's Executive Vice President, General Counsel, and Secretary, Stacy L. Cozad, resigned on June 26, 2024. Ryan C. Fisher, who previously served as Vice President, Deputy General Counsel, and Chief Compliance Officer, has been appointed to succeed Cozad as Senior Vice President, General Counsel, and Secretary.
The transition was disclosed in an 8-K filing with the Securities and Exchange Commission. According to the filing, Cozad's resignation was effective immediately, and the company has entered into a transition agreement with her. Under this agreement, Cozad will receive a cash payment of $673,741, which represents the cash value of her unvested restricted stock units that would be forfeited due to her resignation. The payment is subject to applicable taxes and withholdings.
The agreement also stipulates that Cozad will continue to abide by the restrictive covenants outlined in her Amended and Restated Severance and Change of Control Agreement with Ingevity, dated February 17, 2022. These covenants include terms regarding confidentiality, non-competition, and non-solicitation.
Additionally, the transition agreement includes a general release of claims by Cozad in favor of the company, a provision for binding arbitration, and a mutual non-disparagement covenant.
Following her departure, Cozad has agreed to provide reasonable cooperation and assistance to Ingevity in connection with matters related to her previous duties or events that occurred during her tenure. Ingevity will reimburse Cozad for any reasonable and necessary out-of-pocket expenses incurred during this assistance.
Ingevity, headquartered in North Charleston, South Carolina, operates under the Chemicals & Allied Products industry as per the Standard Industrial Classification system.
In other recent news, Ingevity Corporation has reported a strong start to the first quarter of 2024, with key segments exceeding expectations, particularly the Performance Materials segment which delivered robust margins. The company maintained its full-year guidance, projecting sales between $1.4 billion and $1.55 billion and adjusted EBITDA from $365 million to $390 million.
However, Ingevity also faces persistent challenges with its Crude Tall Oil operations, which are expected to continue into the third quarter.
BMO Capital Markets recently adjusted its price target for Ingevity, raising it to $55.00 from the previous target of $50.00, while retaining its Market Perform rating on the stock. This adjustment is due to the company's strong performance at the start of the year, despite a conservative outlook for the second half.
Loop Capital also increased its price target for Ingevity to $56, reflecting a positive outlook on the company's Performance Materials segment, which is expected to continue its strong performance.
Ingevity is actively exploring alternatives for its AFA/OLEO-based products within its Performance Chemicals division. However, the timeline for the adoption and ramp-up of these alternatives remains uncertain. Despite these recent developments, both BMO Capital Markets and Loop Capital express a neutral stance on the risk/reward balance for Ingevity's stock due to ongoing transformations and uncertainties.
InvestingPro Insights
In light of the recent executive changes at Ingevity Corporation (NYSE:NGVT), investors may be keen to understand the company's financial health and future prospects. According to InvestingPro, management's active share buyback strategy signals confidence in the company's value, which is a positive indicator for shareholders. Additionally, despite a challenging revenue environment with a slight decline over the last twelve months, analysts are optimistic about Ingevity's profitability, expecting net income to grow this year.
InvestingPro data shows a current market capitalization of $1.59 billion and a forward P/E ratio of 21.99, suggesting that investors are anticipating higher earnings in the future. The revenue for the last twelve months stood at $1.639 billion, with a gross profit margin of 28.17%, indicating a strong ability to convert sales into profit. Moreover, with the stock price currently at $43.71, it is trading below the InvestingPro fair value estimate of $48.78, which could imply potential for upside.
For investors looking for more in-depth analysis and additional metrics, there are more InvestingPro Tips available on the platform. Ingevity's stock volatility and the recent revisions of earnings estimates by analysts could be crucial for making informed decisions. Use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, and explore the range of insights offered, including several more tips that can further guide your investment in Ingevity.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.